Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07018401 · ClinicalTrials.gov registry record
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study
A clinical trial of Hereditary Hemorrhagic Telangiectasia (HHT), sponsored by Massachusetts General Hospital.
- Active
- Registry status
- 62
- Enrollment target
- 11
- Study locations
NCT07018401: Active study of Hereditary Hemorrhagic Telangiectasia (HHT), sponsored by Massachusetts General Hospital.
NCT07018401 is a study of Hereditary Hemorrhagic Telangiectasia (HHT) that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 62 participants, roughly in line with the 66-participant average among 3 other Hereditary Hemorrhagic Telangiectasia (HHT) trials with a reported enrollment target. The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07018401, a study of Hereditary Hemorrhagic Telangiectasia (HHT), is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 62 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a multicenter U.S. longitudinal study evaluating patients with hereditary hemorrhagic telangiectasia who participated in the PATH-HHT clinical trial of pomalidomide for the treatment of HHT. This study is a longitudinal assessment of safety and effectiveness of pomalidomide in HHT in clinical trial participants following completion of the double-blind, placebo-controlled study.
Primary Outcome
Validated bleeding scale in HHT scored between 0-10, higher scores indicate worse bleeding
Conditions Studied
Interventions
- DRUG Pomalidomide
Study Locations (11)
California
- University of California-San Diego - San Diego
- University of California-San Francisco - San Francisco
Florida
- University of Florida - Gainesville
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
North Carolina
- University of North Carolina, Chapel HIll - Chapel Hill
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2026-06-01 |
What the registry record for NCT07018401 still lists
NCT07018401 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 62 participants, a relatively small participant target, roughly in line with the 66-participant average among 3 other Hereditary Hemorrhagic Telangiectasia (HHT) trials with a reported enrollment target.
The record links to 1 condition, with Hereditary Hemorrhagic Telangiectasia (HHT) appearing as the primary indexed condition, and to 1 intervention - of which Pomalidomide is the first listed.
NCT07018401 lists 11 locations in 10 states (California, Florida, Maryland).
Frequently Asked Questions
What is clinical trial NCT07018401 about?
NCT07018401 is a clinical study titled "Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study". This is a multicenter U.S. longitudinal study evaluating patients with hereditary hemorrhagic telangiectasia who participated in the PATH-HHT clinical trial of pomalidomide for the treatment of HHT. This study is a longitudinal assessment of safety and effectiveness of pomalidomide in HHT in clinica...
What is the current status of trial NCT07018401?
This trial is currently active not recruiting. The enrollment target is 62 participants. The study started on 2024-05-01. Estimated completion is 2026-06-01.
What conditions does trial NCT07018401 study?
This clinical trial studies the following conditions: Hereditary Hemorrhagic Telangiectasia (HHT).
What interventions are being tested in trial NCT07018401?
The interventions under investigation include: Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT07018401?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07018401 being conducted?
This trial has 11 study locations across California, Florida, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Hemorrhagic Telangiectasia (HHT)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI